William J. Gradishar, MD | Authors

Management of Metastatic HER2-Positive Breast Cancer: Where Are We and Where Do We Go From Here?

February 15, 2016

This review will summarize the current standard of care; key issues that arise when treating patients with HER2-positive disease; and developments in novel therapeutics, including small-molecule inhibitors, nanoparticles, immunotherapy, and agents targeting resistance pathways.

The Role of Ovarian Suppression in Premenopausal Women With Hormone Receptor–Positive Early-Stage Breast Cancer

July 15, 2015

Here, we provide an in-depth review of the current evidence for the addition of ovarian suppression to adjuvant endocrine therapy, and we offer recommendations for clinical management.

Introduction: Skeletal Issues and Bone Health in Patients With Cancer

December 31, 2009

In addition to the direct effects of primary tumors in bone, bone complications in cancer patients occur from metastasis to bone and through the effects of cancer-related treatments and conditions. Bone is a very common metastatic site for many cancers, including myeloma, melanoma, and breast, prostate, thyroid, lung, bladder, and kidney cancers. Metastatic bone lesions can be osteolytic (bone destruction resulting from increased bone resorption and reduced formation), osteoblastic (increased bone formation), or both.

Optimizing Cytotoxic Chemotherapy: New Insights

March 01, 2007

Progress continues in the investigation of cytotoxicchemotherapy for breast cancer, and recentdata have yielded important new insights.

Commentary (Kaklamani/Gradishar): Adjuvant Hormonal Therapy in Early Breast Cancer

October 01, 2005

The use of adjuvant endocrinetherapy in early-stage breastcancer is thought to eradicatemicrometastatic disease that may leadto systemic recurrences. Until relativelyrecently, the standard adjuvantendocrine therapy option was tamoxifen.Data from the Early Breast CancerTrialists’ Collaborative Group(EBCTCG) overview analysis reporteda 50% reduction in the risk of relapseand a 28% reduction in the riskof death in estrogen receptor (ER)-positive patients treated with 5 yearsof tamoxifen.[1] This benefit was observedregardless of menopausal orlymph node status and whether or notpatients were receiving chemotherapy.There was no such benefit documentedin ER-negative cancersreceiving tamoxifen. Tamoxifen hasalso been associated with a 47% reductionin the risk of developing contralateralbreast cancer.[1]

Long-Term Toxicities of Selective Estrogen-Receptor Modulators and Antiaromatase Agents

May 01, 2003

With the advent of aromataseinhibitor use in the adjuvantsetting,[1] and the inceptionof trials examining their usefor breast cancer prevention, it seemsprudent to evaluate what we know todate about the long-term effects of these agents. Unfortunately, unlike selectiveestrogen-receptor modulators(SERMs)-in particular tamoxifen,[2]which has been used for over 15 yearsin patients with early-stage breast cancer-long-term data on the use of aromataseinhibitors are minimal.

Selective Estrogen-Receptor Modulators in 2001

September 01, 2001

Tamoxifen (Nolvadex), a selective estrogen-receptor modulator, or SERM, is currently the endocrine therapy of choice for all stages of hormone-responsive breast cancer. Only tamoxifen has been approved by the US Food and